Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer
Conditions
- Recurrent Head and Neck Carcinoma
- Recurrent Salivary Gland Carcinoma
- Recurrent Skin Carcinoma
- Skin Squamous Cell Carcinoma
Interventions
- DRUG: Erlotinib Hydrochloride
- OTHER: Laboratory Biomarker Analysis
Sponsor
M.D. Anderson Cancer Center
Collaborators